No, Lysteda (tranexamic acid) is contraindicated in women with a history of blood clots
Lysteda is absolutely contraindicated in women with a prior history of venous thromboembolism (VTE). The FDA drug label explicitly states that tranexamic acid is contraindicated in women with "active thromboembolic disease or with a history or intrinsic risk for thrombosis or thromboembolism" 1.
Key Safety Considerations
FDA Contraindications
The official prescribing information for Lysteda clearly prohibits its use in patients with:
- Active thromboembolic disease
- History of thrombosis or thromboembolism
- Intrinsic risk for thrombosis or thromboembolism 1
This is a black-and-white contraindication that should not be violated in routine clinical practice.
Evidence on Thrombotic Risk
The thrombotic risk with oral tranexamic acid for menorrhagia is real and quantifiable. A large Danish nationwide cohort study of 2 million women found that oral tranexamic acid use was associated with a 4-fold increased risk of venous thromboembolism (adjusted incidence rate ratio 4.0,95% CI 1.8-8.8) 2. While the absolute risk remains relatively low (number needed to harm of 78,549 per 5 days of treatment), this represents a significant relative risk increase that is unacceptable in someone with prior VTE.
Additional supporting evidence includes:
- A case-control study showing an adjusted odds ratio of 3.20 (95% CI 0.65-15.78) for VTE with tranexamic acid use, though not reaching statistical significance 3
- Case reports of recurrent pulmonary embolism in patients with prior PE who used tranexamic acid 4
Important Distinction: Acute Bleeding vs. Elective Use
There is a critical distinction between using tranexamic acid for active, life-threatening bleeding versus elective treatment of heavy menstrual bleeding:
In emergency bleeding situations (trauma, postpartum hemorrhage, surgical bleeding), recent 2025 guidelines indicate that tranexamic acid should be administered according to the same indications regardless of anticoagulant use or thrombotic history, as the immediate mortality benefit from controlling life-threatening hemorrhage outweighs thrombotic risk 5
For elective treatment of heavy menstrual bleeding (the indication for Lysteda), the risk-benefit calculation is entirely different. There is no immediate life-threatening situation, and alternative treatments exist. The FDA contraindication applies here.
Alternative Management Options
For women with prior VTE who have heavy menstrual bleeding, consider:
Levonorgestrel-releasing intrauterine system (LNG-IUD) - More effective than tranexamic acid for reducing menstrual blood loss 6
NSAIDs (mefenamic acid, ibuprofen) - Reduce menstrual blood loss by 20-50%, though less effective than tranexamic acid 1
Hormonal options - Combined oral contraceptives are contraindicated with prior VTE 7, but progestin-only methods may be considered after careful risk assessment
Surgical interventions - Endometrial ablation or hysterectomy for refractory cases
Clinical Pitfalls to Avoid
Do not rationalize use based on surgical data: Studies showing safety of tranexamic acid in arthroplasty patients with prior VTE 8 or general surgery 9 do not apply to the chronic, elective use scenario of treating menorrhagia
Do not confuse emergency and elective indications: The 2025 guidelines supporting tranexamic acid use in patients on anticoagulants specifically address acute bleeding emergencies, not chronic menorrhagia management 5
Respect the FDA contraindication: This is not a "relative" contraindication that can be overcome with monitoring—it is an absolute contraindication for the Lysteda indication
The bottom line: A woman with a history of blood clots should not receive Lysteda for heavy menstrual bleeding. Alternative treatments must be pursued.